Thrombolytic therapy for acute pulmonary embolism: when do the benefits exceed the risks?

Am J Med. 2014 Nov;127(11):1031-1032. doi: 10.1016/j.amjmed.2014.06.039. Epub 2014 Jul 11.

Authors

Paul D Stein¹, James E Dalen²

Affiliations

¹ Professor, Osteopathic Medical Specialties, Michigan State University College of Osteopathic Medicine, Detroit. Electronic address: [email protected].
² Dean Emeritus and Professor Emeritus, University of Arizona College of Medicine, Tucson.

PMID: 25019361
DOI: 10.1016/j.amjmed.2014.06.039

No abstract available

MeSH terms

Anticoagulants / therapeutic use
Fibrinolytic Agents / therapeutic use
Humans
Intracranial Hemorrhages / chemically induced
Pulmonary Embolism / drug therapy*
Pulmonary Embolism / mortality
Randomized Controlled Trials as Topic
Risk Assessment
Shock / mortality
Thrombolytic Therapy*
Ventricular Dysfunction, Right / mortality

Substances

Anticoagulants
Fibrinolytic Agents